[{"from": "human", "value": "Describe this molecule. [C][C@H1][/C][=C][/C@@H1][Branch2][Ring2][N][C@][Branch2][Ring2][Ring2][C][C][C@H1][Branch2][Ring1][=N][C][C][=Branch1][C][=O][O][C@@H1][Ring1][=N][/C][=Branch1][S][=C][/C][=C][/C@@H1][Branch1][C][C][C][=C][C][=C][C][=N][Ring1][=Branch1][/C][O][Branch1][C][C][O][O][C][=Branch1][C][=O][N][C][C][N][Branch1][Branch1][C][C][Ring1][=Branch1][C]"}, {"from": "gpt", "value": "The molecule is a novel spliceosome inhibitor developed by H3 Biomedicine. It offers the benefit of preferentially killing spliceosome-mutant cancer cells whereas other splicesome inhibitors, such as the pladienolide analogue E7107, show no such preferential targeting. H3B-8800 was granted orphan drug status by the FDA in August 2017 and is in clinical trials for the treatment of acute myelogenous leukemia and chronic myelomonocytic leukemia."}]